Caris Life Sciences Stock

carislifesciences.com | BioTech | Funding to Date: $465,000,000

Operator of a biotechnology company specializing in cancer treatment agents. The company is a provider of molecular science focused on fulfilling the promise of precision medicine and facilitating a deeper understanding of cancer biology and other complex diseases through a suite of molecular profiling offerings assess DNA, RNA and proteins that reveal the molecular blueprint, enabling physicians and cancer patients to make more precise and personalized treatment decisions.

TEAM

Management Team
  • David Halbert - Co-Founder, Chairman and Chief Executive Officer
  • David Spetzler Ph.D - President & Chief Scientific Officer
  • Thomas Parker - Chief Financial Officer and Senior Vice President
  • Ginger Appleberry JD - Chief Compliance Officer & Associate General Counsel
  • Ronald Merlino - Senior Vice President & Chief Information Officer
  • Stephanie Thomas - Chief of Staff, Executive Vice President & Office of the CEO
  • Brian Lamon Ph.D - Chief Business Officer & Head of BioPharma Business Development
  • Jim Abraham - Chief Data Officer & Senior Vice President
Board Members
  • Brian Brille JD - Caris Life Sciences
  • Danny Phillips -
  • David Halbert - Caris Life Sciences
  • George Poste Ph.D -
  • Jon Halbert - Caris Life Sciences
  • Jonathan Knowles Ph.D - Caris Life Sciences
  • Laurie Johansen JD - Caris Life Sciences
  • Peter Castleman - J.H. Whitney Capital Partners
  • Vijay Mohan - Sixth Street Specialty Lending

Other companies like Caris Life Sciences in the BioTech sector

Ginkgo Bioworks
BioTech
Est. Val.: $4.89B
Human Longevity
BioTech
Est. Val.: $50,396,793
Caribou Biosciences
BioTech
Est. Val.: $143,800,000
Life Biosciences
BioTech
Est. Val.: $500,000,000
American Gene Technologies International
BioTech
Est. Val.: $265,000,000
Mammoth Biosciences
BioTech
Est. Val.: $145,000,000
X